



Axovant Sciences to Present at the 35th Annual J.P. Morgan Healthcare Conference

December 15, 2016

BASEL, Switzerland, Dec. 15, 2016 /PRNewswire/ -- Axovant Sciences (NYSE: **AXON**), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the 35th Annual J.P. Morgan Healthcare Conference on January 10 at 12:00 p.m. PST.

A simultaneous webcast will be available in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following the conference.

About Axovant

Axovant Sciences is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-300378890.html>

SOURCE Axovant Sciences

Contact:

Jonathan Neely
Head, Investor Relations and Corporate Communications
Axovant Sciences, Inc.
(212) 634-9744